Ponatinib in childhood Philadelphia chromosome–positive leukaemias: an international registry of childhood chronic myeloid leukaemia study

癌症研究 髓系白血病
作者
Frédéric Millot,Meinolf Suttorp,Birgitta A. B. Versluys,Krzysztof Kałwak,Brigitte Nelken,Stéphane Ducassou,Yves Bertrand,André Baruchel
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:136: 107-112 被引量:31
标识
DOI:10.1016/j.ejca.2020.05.020
摘要

Background Ponatinib is effective in adults with Philadelphia chromosome–positive (Ph+) leukaemias, but scant data are available regarding the use of this tyrosine kinase inhibitor in children. Aims The aim of this study isto describe the tolerance and efficacy of compassionate use of ponatinib in a paediatric cohort of patients with Ph+ leukaemias. Methods Data from 11 children with chronic myeloid leukaemia (CML) registered to the international registry of childhood chronic myeloid leukaemia and from 3 children with Ph+ acute lymphoblastic leukaemia (Ph+ ALL) treated with ponatinib were collected retrospectively. Results In 11 girls and 3 boys (median age 14 years), ponatinib was used as a second- to eighth-line treatment. Ponatinib was administered as single therapy (9 patients) or in combination with chemotherapy (8 patients). The status of the disease when ponatinib was started was as follows: CML in advanced phases (n = 8), CML in chronic phase without achievement of molecular response (n = 2) or presence of T315I mutation (n = 1) and Ph + ALL in molecular (n = 1) or marrow (n = 2) relapses. The median dose administered was 21.4 mg/m 2 and median duration of ponatinib was 2.5 months. Ponatinib alone or in combination with chemotherapy administered on 16 occasions led to achievement of major molecular response in 50% of cases. Ponatinib was used as a bridge to transplant in 4 cases. Among the 9 patients treated with ponatinib alone, toxicity grade III–IV (2 patients) was exclusively haematologic. No vascular events related to ponatinib were observed. Conclusion Ponatinib may be a reasonable additional treatment option for children with Ph+ leukaemias who have failed several lines of therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
yue完成签到,获得积分10
1秒前
1秒前
2秒前
3秒前
丘比特的应助被最好的采纳,获得10
3秒前
一杯芝士发布了新的文献求助10
4秒前
桐桐的应助被风中的宛白采纳,获得10
4秒前
4秒前
渣渣兔完成签到,获得积分10
4秒前
4秒前
张哈哈完成签到,获得积分10
4秒前
leye发布了新的文献求助10
4秒前
帕克完成签到,获得积分10
5秒前
实验室发布了新的文献求助10
5秒前
ZeKaWa的应助被健壮的大有采纳,获得10
5秒前
无限芸遥发布了新的文献求助10
5秒前
5秒前
帅斌完成签到,获得积分10
6秒前
syyy发布了新的文献求助10
6秒前
余漆完成签到,获得积分10
6秒前
阿斯顿风格完成签到,获得积分10
7秒前
7秒前
Vicktor2021完成签到,获得积分10
8秒前
吗喽发布了新的文献求助10
9秒前
10秒前
10秒前
syyy完成签到,获得积分10
11秒前
11秒前
ssc完成签到,获得积分10
12秒前
mmol发布了新的文献求助10
12秒前
null完成签到,获得积分0
12秒前
风趣忻发布了新的文献求助10
12秒前
赘婿的应助被流苏采纳,获得10
13秒前
daddadadada完成签到 ,获得积分10
13秒前
阳光的半雪完成签到,获得积分10
13秒前
胖三斤完成签到,获得积分10
13秒前
nyh完成签到 ,获得积分10
13秒前
桃桃发布了新的文献求助10
13秒前
噫吁嚱发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651